Peter Doshi

Peter Doshi is an associate professor of pharmaceutical health services research at the University of Maryland School of Pharmacy and a senior editor at The BMJ. Based in Baltimore, his academic work focuses on the drug approval process, risk-benefit assessment of medical products, and improving the credibility of evidence synthesis. He leads the Restoring Invisible and Abandoned Trials (RIAT) Support Center, which addresses publication bias and reporting bias in clinical trials.

Dr. Doshi's educational background spans multiple disciplines, reflecting his interdisciplinary approach to pharmaceutical research:

• A.B. in Anthropology from Brown University
• A.M. in East Asian Studies from Harvard University
• Ph.D. in History, Anthropology, and Science, Technology and Society from MIT
• Fellowship in Comparative Effectiveness Research at Johns Hopkins University

His research interests center on pharmaceutical regulation, clinical trial transparency, and evidence-based medicine. Dr. Doshi has been particularly active in examining the science and politics of influenza policy and has published extensively on neuraminidase inhibitors for influenza. More recently, he has focused on transparency issues in COVID-19 vaccine trials, advocating for greater access to raw trial data and raising methodological questions about vaccine efficacy assessments. His work often bridges historical, anthropological, and scientific perspectives to critically examine pharmaceutical evidence generation.

Dr. Doshi has received significant recognition for his work, including:

• New Investigator Award from the American Association of Colleges of Pharmacy (2015)
• Selection for The Wired 'Smart List' (2013)
• Feature in The New York Times for work on clinical trial data access (2013)

As principal investigator, Dr. Doshi has secured substantial grant funding, including a $1.4 million grant from Arnold Ventures (2017-2022) for the RIAT Support Center and a current $253,243 grant from Arnold Ventures for evaluating and improving consent in clinical trials. His publications reveal a consistent focus on methodological rigor and transparency across pharmaceutical research domains, with recent work critically examining vaccine trial design, data interpretation, and regulatory processes.

Dr. Doshi maintains an active role in shaping discourse around pharmaceutical regulation, regularly presenting to bodies like the Institute of Medicine and serving on advisory panels to the European Medicines Agency. His dual role as academic researcher and senior editor at The BMJ creates a unique platform for influencing both research practices and scientific communication in the pharmaceutical field.